Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lupus care under the microscope: new registry tracks Real-World treatment in kazakhstan

NCT ID NCT06899633

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study is a registry that will follow about 500 adults with lupus (SLE) in Kazakhstan to see how the disease behaves and how doctors treat it in everyday practice. Researchers will look at disease activity, organ damage, and which medications are used. No new treatments are being tested—the goal is simply to collect information to better understand lupus care in this region.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could reveal how lupus is actually managed in Kazakhstan, pointing to gaps in care and opportunities to improve treatment guidelines.
What could go wrong
This is an observational study, not a treatment trial. It collects data only and cannot directly improve patient outcomes. Results may not apply outside Kazakhstan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

509 people

The number who actually took part.

Started

May 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This non-interventional, multicenter observational study will enroll 500 adult patients with established SLE who are being followed and treated by rheumatologists in approximately 10 outpatient sites in approximately 8 regions of Kazakhstan. Eligible patients will be recruited sequentially during routine hospital visits. There will be no patient recruitment restrictions per site or region (to minimize selection bias at each site).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Men and women aged 18 years and older with a verified diagnosis of SLE * Patient signed and dated written informed consent form (ICF) by ICH GCP and local legislation prior to inclusion in the study for the prospective observational group. Exclusion Criteria * Absence of a signed consent form (ICF) in patients * Cognitive impairments that hinder understanding the study objectives and completing questionnaires * Participation in any randomized controlled clinical trial within 3 months prior to inclusion or during participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Description of methods and approaches to the treatment of patients with SLE in the republic of kazakhstan are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Description of methods and approaches to the treatment of patients with SLE in the republic of kazakhstan Description of SLE activity in patients in routine practice in the republic of kazakhstan Description of the course of SLE in patients in the republic of kazakhstan

Contacts and locations

Locations

  • ESEM Pharmacy LLP

    Almaty, Kazakhstan

  • JSC Research Institute of Cardiology and Internal Diseases

    Almaty, Kazakhstan

  • Medical Center for Joint Diseases of Shymkent LLP

    Shymkent, Kazakhstan

  • Municipal State Enterprise on the Right of Economic Management - Pavlodar Regional Hospital named after G. Sultanov

    Pavlodar, Kazakhstan

  • Municipal state enterprise with the right of economic management City polyclinic No. 5

    Almaty, Kazakhstan

  • Non-Profit Joint Stock Company Kazakh National Medical University named after S.D. Asfendiyarov

    Almaty, Kazakhstan

  • Non-Profit Joint Stock Company Semey Medical University - University Hospital

    Semey, Kazakhstan

  • Republican Diagnostic Center of Astana Corporate Fund University Medical Center

    Astana, Kazakhstan

  • State Enterprise on the Right of Economic Management - Aktobe Medical Center

    Aktobe, Kazakhstan

  • State Enterprise on the Right of Economic Management - Regional Clinical Hospital of the Turkestan Region

    Shymkent, Kazakhstan

  • State-owned enterprise on the right of economic management -Taldykorgan City Polyclinic

    Taldykorgan, Kazakhstan

  • Zhambyl Regional Multidisciplinary Hospital of the Health Department of the Akimat of Zhambyl Region

    Taraz, -- Select --, Kazakhstan

More trials for these conditions

Other studies related to the condition(s) this trial covers.